Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

1078733

USP

Bupropion -hydrochlorid

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(±)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C13H18ClNO · HCl
CAS-Nummer:
31677-93-7
Molekulargewicht:
276.20
MDL-Nummer:
MFCD00055209
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329749161
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

bupropion

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

Cl[H].CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

InChI

1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

InChIKey

HEYVINCGKDONRU-UHFFFAOYSA-N

Angaben zum Gen

human ... SLC6A2(6530) , SLC6A3(6531)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Bupropion hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1078744

Bupropionhydrochlorid-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1078755

Bupropionhydrochlorid-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1078766

Bupropionhydrochlorid-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

1078799

Bupropionhydrochlorid-verwandte Verbindung F, United States Pharmacopeia (USP) Reference Standard

1078846

Bupropion -hydrobromid, United States Pharmacopeia (USP) Reference Standard

1112299

3-Chlorbenzoesäure, United States Pharmacopeia (USP) Reference Standard

PHR1744

3-Chlorbenzoesäure, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1752

Bupropion-Hydrochlorid-verwandte Verbindung A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1753

Bupropionhydrochlorid-verwandte Verbindung B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1755

Bupropion-verwandte Verbindung F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1754

Bupropion-verwandte Verbindung C, Pharmaceutical Secondary Standard; Certified Reference Material

1078857

Bupropion Related Compound G, United States Pharmacopeia (USP) Reference Standard

1117020

Chloropropiophenone, United States Pharmacopeia (USP) Reference Standard

PHR3178

Bupropion-Hydrobromid, pharmaceutical secondary standard, certified reference material

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

(±)-Hydroxybupropion-D6 -Lösung 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-062

(±)-Hydroxybupropion-D6 -Lösung

Supelco

Supelco

PHR1754

Bupropion-verwandte Verbindung C

100&#160;&#956;g/mL in methanol, ampule of 1&#160;mL, certified reference material, Cerilliant<SUP>&#174;</SUP>

Supelco

B-052

(±)-Bupropion-D9 hydrochloride solution

1.0&#160;mg/mL in acetonitrile, ampule of 1&#160;mL, certified reference material, Cerilliant<SUP>&#174;</SUP>

Supelco

H-066

(±)-Hydroxybupropion solution

Phenacetin &#8805;98.0% (HPLC)

Sigma-Aldrich

77440

Phenacetin

Diclofenac Natriumsalz

Sigma-Aldrich

D6899

Diclofenac Natriumsalz

Sergios Charntikov et al.
Neuropharmacology, 86, 181-191 (2014-08-01)
Bupropion is an atypical antidepressant that increases long-term quit rates of tobacco smokers. A better understanding of the relation between nicotine and this first-line medication may provide insight into improving treatment. For all experiments, rats first had nicotine (0.4 mg base/kg)
R L Dufresne et al.
Drug intelligence & clinical pharmacy, 18(12), 957-964 (1984-12-01)
Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans. It neither is sedating, anticholinergic, nor cardiotoxic. Its mechanism of action may be related to dopamine, but remains uncertain at this time. Clinical trials comparing bupropion 300-750
Marlene P Freeman
The American journal of psychiatry, 171(7), 723-728 (2014-07-02)
Attention deficit hyperactivity disorder (ADHD) has been increasingly recognized and treated in children and adults in recent years. As a result, a growing number of women enter their reproductive years treated with medication for ADHD or are diagnosed and start
S H Preskorn et al.
Pharmacotherapy, 4(1), 20-34 (1984-01-01)
Bupropion hydrochloride is a new antidepressant that differs clinically and pharmacologically from the tricyclic antidepressants and the monoamine oxidase inhibitors. Pharmacokinetically, bupropion is an intermediate-lived drug with a half-life of about 12 hours. Its antidepressant activity in man has been
Theresa M Winhusen et al.
The Journal of clinical psychiatry, 75(4), 336-343 (2013-12-19)
To evaluate the impact of concurrent treatments for substance use disorder and nicotine-dependence for stimulant-dependent patients. A randomized, 10-week trial with follow-up at 3 and 6 months after smoking quit date conducted at 12 substance use disorder treatment programs between
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.